nach oben

Erschienen in:

03.05.2016 | Original Article

Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy

verfasst von: Eiryu Sai, Kazunori Shimada, Takayuki Yokoyama, Makoto Hiki, Shuji Sato, Nozomi Hamasaki, Masaki Maruyama, Ryoko Morimoto, Tetsuro Miyazaki, Shinichiro Fujimoto, Yoshifumi Tamura, Shigeki Aoki, Hirotaka Watada, Ryuzo Kawamori, Hiroyuki Daida

Erschienen in: Heart and Vessels | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Proton magnetic resonance spectroscopy (¹H-MRS) enables the assessment of myocardial triglyceride (TG) content, which is reported to be associated with cardiac dysfunction and morphology accompanied by metabolic disorder and cardiac hemodynamic status. The clinical usefulness of myocardial TG content measurements in patients with left ventricular hypertrophy (LVH) has not been fully investigated. We examined whether myocardial TG content assessed by ¹H-MRS was useful for diagnosis in patients with LVH. To quantify myocardial TG content, we conducted ¹H-MRS in 35 subjects with LVH. Left ventricular function was measured by cardiac magnetic resonance imaging. Patients were assigned to a hypertensive heart disease (HHD, n = 10) or hypertrophic cardiomyopathy (HCM, n = 25) group based on the histology and/or late gadolinium enhancement pattern. The myocardial TG content was significantly higher in the HHD group than in the HCM group (2.14 ± 1.29 vs. 1.09 ± 0.72 %, P < 0.001). Myocardial TG content were significantly and negatively correlated with LV mass (r = −0.41, P < 0.04) and stroke volume (r = −0.64, P < 0.05) in the HCM group and HHD group, respectively. In a multivariate analysis, LV mass volume and diagnosis of HCM or HHD were independent factors of the myocardial TG content. The results suggest that myocardial metabolism may differ between HCM and HHD patients and that measurement of myocardial TG content by ¹H-MRS may be useful for evaluating the myocardial metabolic features of LVH.

Nur mit Berechtigung zugänglich

Hoey ET, Elassaly M, Ganeshan A, Watkin RW, Simpson H (2014) The role of magnetic resonance imaging in hypertrophic cardiomyopathy. Quant Imaging Med Surg 4:397–406PubMedPubMedCentral

Kawashiri MA, Hayashi K, Konno T, Fujino N, Ino H, Yamagishi M (2014) Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects. Heart Vessels 29:129–141CrossRefPubMed

Lorell BH, Carabello BA (2000) Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102:470–479CrossRefPubMed

Hanatani S, Izumiya Y, Takashio S, Kojima S, Yamamuro M, Araki S, Rokutanda T, Tsujita K, Yamamoto E, Tanaka T, Tayama S, Kaikita K, Hokimoto S, Sugiyama S, Ogawa H (2014) Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts. Heart Vessels 29:231–237CrossRefPubMed

Nabeta T, Inomata T, Iida Y, Ikeda Y, Iwamoto M, Ishii S, Sato T, Watabnabe I, Naruke T, Shinagawa H, Koitabashi T, Takeuchi I, Nishii M, Inoue Y, Izumi T (2014) Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy. Heart Vessels 29:784–792CrossRefPubMed

Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, De Santis M, Quarta G, Nistri S, Cecchi F, Salton CJ, Udelson JE, Manning WJ, Maron BJ (2008) Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 52:559–566CrossRefPubMed

Cramer G, Bakker J, Gommans F, Brouwer M, Kurvers M, Fouraux M, Verheugt F, Kofflard M (2014) Relation of highly sensitive cardiac troponin T in hypertrophic cardiomyopathy to left ventricular mass and cardiovascular risk. Am J Cardiol 113:1240–1245CrossRefPubMed

Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, Lesser JR, Gruner C, Crean AM, Rakowski H, Udelson JE, Rowin E, Lombardi M, Cecchi F, Tomberli B, Spirito P, Formisano F, Biagini E, Rapezzi C, De Cecco CN, Autore C, Cook EF, Hong SN, Gibson CM, Manning WJ, Appelbaum E, Maron MS (2014) Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130:484–495CrossRefPubMed

Chan RH, Maron BJ, Olivotto I, Assenza GE, Haas TS, Lesser JR, Gruner C, Crean AM, Rakowski H, Rowin E, Udelson J, Lombardi M, Tomberli B, Spirito P, Formisano F, Marra MP, Biagini E, Autore C, Manning WJ, Appelbaum E, Roberts WC, Basso C, Maron MS (2015) Significance of late gadolinium enhancement at right ventricular attachment to ventricular septum in patients with hypertrophic cardiomyopathy. Am J Cardiol 116:436–441CrossRefPubMed

10.

Hen Y, Iguchi N, Machida H, Takada K, Utanohara Y, Sumiyoshi T (2013) High signal intensity on T2-weighted cardiac magnetic resonance imaging correlates with the ventricular tachyarrhythmia in hypertrophic cardiomyopathy. Heart Vessels 28:742–749CrossRefPubMed

11.

McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Ungr R, Levine BD, Raskin P, Victor RG, Szczepaniak LS (2007) Cardiac steatosis in diabetes mellitus: a ¹H-magnetic resonance spectroscopy study. Circulation 116:1170–1175CrossRefPubMed

12.

Kankaanpaa M, Lehto HR, Parkka JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Lozzo P (2006) Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 91:4689–4695CrossRefPubMed

13.

Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D’Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG (2003) Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med 49:417–423CrossRefPubMed

14.

Unger RH (2003) The physiology of cellular liporegulation. Annu Rev Physiol 65:333–347CrossRefPubMed

15.

van der Meer RW, Rijzewijk LJ, Diamant M, Hammer S, Schar M, Bax JJ, Smit JW, Romijn JA, de Roos A, Lamb HJ (2008) The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J 29:1516–1522CrossRefPubMed

16.

Christoffersen C, Bollano E, Lindegaard ML, Bartels ED, Goetze JP, Andersen CB, Nielsen LB (2003) Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. Endocrinology 144:3483–3490CrossRefPubMed

17.

Mahmod M, Bull S, Suttie JJ, Pal N, Holloway C, Dass S, Myerson SG, Schneider JE, De Silva R, Petrou M, Sayeed R, Westaby S, Clelland C, Francis JM, Ashrafian H, Karamitsos TD, Neubauer S (2013) Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis. Circ Cardiovasc Imaging 6:808–816CrossRefPubMed

18.

Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, Egusa G, Hiro T, Hirobe K, Iida M, Kihara S, Kinoshita M, Maruyama C, Ohta T, Okamura T, Yamashita S, Yokode M, Yokote K (2013) Diagnostic criteria for dyslipidemia. J Atheroscler Thromb 20:655–660CrossRefPubMed

19.

Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ (2008) Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 1:184–191CrossRefPubMed

20.

Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, Bonow RO, Judd RM, Kim RJ (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156–2164CrossRefPubMed

21.

Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH 3rd, Spirito P, Ten Cate FJ, Wigle ED (2003) American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMed

22.

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H (2014) 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779CrossRefPubMed

23.

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelista A (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22:107–133CrossRefPubMed

24.

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463CrossRef

25.

Chai JW, Chen WH, Chen HM, Chiang CM, Huang JL, Fu J, Chi-Chang Chen C, Lee SK (2011) Correction of left ventricular wall thickening from short-axis cine MRI for basal-descent through-plane motion. J Magn Reson Imaging 33:464–473CrossRefPubMed

26.

Gandy SJ, Waugh SA, Nicholas RS, Simpson HJ, Milne W, Houston JG (2008) Comparison of the reproducibility of quantitative cardiac left ventricular assessments in healthy volunteers using different MRI scanners: a multicenter simulation. J Magn Reson Imaging 28:359–365CrossRefPubMed

27.

den Hollander JA, Evanochko WT, Pohost GM (1994) Observation of cardiac lipids in humans by localized ¹H magnetic resonance spectroscopic imaging. Magn Reson Med 32:175–180CrossRef

28.

Felblinger J, Jung B, Slotboom J, Boesch C, Kreis R (1999) Methods and reproducibility of cardiac/respiratory double-triggered (1)H-MR spectroscopy of the human heart. Magn Reson Med 42:903–910CrossRefPubMed

29.

McGavock JM, Victor RG, Unger RH, Szczepaniak LS (2006) Adiposity of the heart, revisited. Ann Intern Med 144:517–524CrossRefPubMed

30.

Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O (1993) Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn Reson Med 29:158–167CrossRefPubMed

31.

Sai E, Shimada K, Yokoyama T, Sato S, Miyazaki T, Hiki M, Tamura Y, Aoki S, Watada H, Kawamori R, Daida H (2013) Association between myocardial triglyceride content and cardiac function in healthy subjects and endurance athletes. PLoS ONE 8:e61604CrossRefPubMedPubMedCentral

32.

Sai E, Shimada K, Yokoyama T, Sato S, Nishizaki Y, Miyazaki T, Hiki M, Tamura Y, Aoki S, Watada H, Kawamori R, Daida H (2015) Evaluation of myocardial triglyceride accumulation assessed on (1)h-magnetic resonance spectroscopy in apparently healthy Japanese subjects. Intern Med 54:367–373CrossRefPubMed

33.

Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E (2013) Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 15:91CrossRefPubMedPubMedCentral

34.

Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO (1994) Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213:263–276CrossRefPubMed

35.

Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A, Lamb HJ (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52:1793–1799CrossRefPubMed

36.

Ono T, Kohya T, Tsukamoto E, Mochizuki T, Itoh K, Itoh Y, Tomit F, Tamaki N, Kitabatake A (2000) Improvement in fatty acid utilization in relation to a change in left ventricular hypertrophy in spontaneously hypertensive rats. Jpn Circ J 64:117–120CrossRefPubMed

37.

Okizaki A, Shuke N, Sato J, Sasaki T, Hasebe N, Kikuchi K, Aburano T (2007) A compartment model analysis for investigation of myocardial fatty acid metabolism in patients with hypertrophic cardiomyopathy. Nucl Med Commun 28:726–735CrossRefPubMed

38.

Abozguia K, Elliott P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M (2010) Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562–1569CrossRefPubMed

39.

Horowitz JD, Chirkov YY (2010) Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. Circulation 122:1547–1549CrossRefPubMed

Titel: Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy
verfasst von: Eiryu Sai
Kazunori Shimada
Takayuki Yokoyama
Makoto Hiki
Shuji Sato
Nozomi Hamasaki
Masaki Maruyama
Ryoko Morimoto
Tetsuro Miyazaki
Shinichiro Fujimoto
Yoshifumi Tamura
Shigeki Aoki
Hirotaka Watada
Ryuzo Kawamori
Hiroyuki Daida
Publikationsdatum: 03.05.2016
Verlag: Springer Japan
Erschienen in: Heart and Vessels / Ausgabe 2/2017
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-016-0844-8

Neu im Fachgebiet Kardiologie

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy

Abstract

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Total arterial grafting is associated with improved clinical outcomes compared to conventional myocardial revascularization at 10 years follow-up

Serum carboxy-terminal telopeptide of type I collagen (I-CTP) is predictive of clinical outcome in peripheral artery disease patients following endovascular therapy

Assessing utility of exercise test in determining exercise prescription in adolescent and adult patients with repaired tetralogy of fallot

Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute myocardial infarction

Interventricular dyssynchrony in a patient with a biventricular physiology and a systemic right ventricle

Ibutilide protects against cardiomyocytes injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways

Neu im Fachgebiet Kardiologie

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Parodontalbehandlung verbessert Prognose bei Katheterablation

Update Kardiologie